Related Experiment Video
Updated: Jun 23, 2026
09:52
Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma
Published on: January 25, 2015
Thoracic stop-flow perfusion for refractory lymphoma: a phase I-II evaluation trial
Cristina Ruscitti1, Stefano Guadagni, Filippo Russo
1Department of Surgical Sciences, University of L'Aquila, Italy.
In Vivo (Athens, Greece)
|May 21, 2009
Summary
Thoracic stop-flow perfusion shows significant activity in heavily pretreated malignant lymphoma patients. This innovative therapy demonstrated favorable responses, including complete remissions, despite the challenging patient population.
Area of Science:
- Oncology
- Hematology
- Surgical Oncology
Background:
- Malignant lymphoma management is challenging in patients refractory to standard treatments.
- Salvage high-dose chemotherapy and autologous stem cell rescue often fail in advanced cases.
- Thoracic stop-flow perfusion is an investigational approach for such difficult-to-treat lymphomas.
Purpose of the Study:
- To evaluate the safety and efficacy of thoracic stop-flow perfusion in patients with heavily pretreated malignant lymphoma.
- To assess response rates and toxicity profiles of this novel perfusion technique.
Main Methods:
- A phase I-II trial enrolled nine refractory lymphoma patients.
- Thoracic stop-flow perfusion utilized cisplatin and melphalan chemotherapy.
- Hemofiltration was employed during procedures to manage toxicity.
- Melphalan pharmacokinetics were analyzed.
Main Results:
- Eighteen cycles of perfusional chemotherapy were administered without technical or surgical complications.
- Hematological and non-hematological toxicity was mild due to hemofiltration.
- All nine patients showed favorable responses, with 5 complete remissions (CR) and 4 partial remissions (PR).
- Long-term remission was observed in one patient (37+ months).
Conclusions:
- Thoracic stop-flow perfusion demonstrates significant activity in refractory malignant lymphoma.
- The procedure is technically feasible and associated with manageable toxicity.
- This approach offers a potential therapeutic option for patients with limited treatment alternatives.
